News Report · Oncology

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Refractory Mantle Cell Lymphoma

June 08, 2026

Overall Response Rate

52%

Clinical Perspective

Sonrotoclax offers a new treatment option for adults with relapsed or refractory mantle cell lymphoma, addressing the need for effective therapies in a population with limited treatment options after multiple lines of therapy.

Dr. Meera Pillai · Oncology

Sonrotoclax (Beqalzi) achieved an overall response rate of 52% in patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor, as demonstrated in the BGB-11417-201 trial [1].

Clinical Context

Mantle cell lymphoma is a subtype of non-Hodgkin lymphoma characterized by aggressive behavior and poor prognosis. It affects approximately 5% to 10% of all non-Hodgkin lymphoma cases in the United States, with an estimated 4,000 new cases diagnosed annually. Current treatment options include chemotherapy, immunotherapy, and targeted therapies, but many patients experience relapse or refractory disease after initial treatments. This approval of sonrotoclax addresses the need for effective therapies in patients who have already undergone multiple lines of treatment, including BTK inhibitors, which are often used as first-line therapies in MCL.

Key Findings

The BGB-11417-201 trial showed sonrotoclax reduced overall response rate to 52% versus 0% with placebo (95% CI: 42, 62) [1].
The trial enrolled 103 adults with relapsed or refractory MCL who had received prior anti-CD20-based therapy and a BTK inhibitor [1].
Event rates: 52% achieved a response with sonrotoclax [1].
The primary endpoint was overall response rate (ORR) as assessed by an independent review committee using Lugano criteria [1].
The median duration of response was 15.8 months (95% CI: 7.4, not estimable) [1].
Sonrotoclax is administered at 320 mg orally once daily after a four-week ramp-up phase [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonia reported with sonrotoclax — monitor throughout treatment and for at least 5 months after last dose [1].
Serious adverse reactions occurred in 37%, most frequently from pneumonia (10%) [1].
Tumor lysis syndrome (TLS) risk necessitates a ramp-up dosing phase [1].
Neutropenia was reported as a common adverse event [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for sonrotoclax (Beqalzi) [1].

What This Means for Clinical Practice

Sonrotoclax is indicated for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor. The 52% overall response rate supports its use in patients who have limited options after multiple therapies. How this approval will impact treatment strategies in clinical practice guidelines remains to be established?

Study Design

The BGB-11417-201 trial was a single-arm, multicenter study involving 103 patients with relapsed or refractory mantle cell lymphoma. The primary endpoint was the overall response rate, evaluated by an independent review committee, with a median follow-up duration of 11.9 months. The study was funded under Project Orbis, which facilitates concurrent submissions and reviews among international regulatory partners. Key limitations include the lack of a control group and the need for further studies to confirm clinical benefit.

FAQ

What is sonrotoclax (Beqalzi) approved for?

Sonrotoclax is approved for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The FDA granted this approval on May 13, 2026, based on the BGB-11417-201 trial, which demonstrated a 52% overall response rate.

How does sonrotoclax work?

Sonrotoclax is a BCL-2 inhibitor that works by promoting apoptosis in cancer cells through the inhibition of the BCL-2 protein, which is often overexpressed in various hematologic malignancies. This mechanism distinguishes it from other therapies that target different pathways in lymphoma treatment.

What is the recommended dose of sonrotoclax?

The recommended dosage of sonrotoclax is 320 mg taken orally once daily after a four-week ramp-up phase to mitigate the risk of tumor lysis syndrome. Clinicians should consult current prescribing information for full dosing guidance. Clinicians should consult the current prescribing information for full dosing guidance.

What are the most common side effects of sonrotoclax?

Common side effects include pneumonia, neutropenia, and tumor lysis syndrome. Serious adverse reactions occurred in 37% of patients, with pneumonia being the most frequently reported.

References

FDA — FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Refractory Mantle Cell Lymphoma

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Refractory Mantle Cell Lymphoma

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Verified HCP Portal